Histological Inflammation Predicts Loss of Remission Among Crohn's Patients with Endoscopic Remission: A US Cohort Analysis

This is the companion Crohn's disease analysis to the UC LOR study (Row 15 / Row 4 manuscript). Earlier UEGW 2021 poster presentation establishing that histologic inflammation in CD endoscopic remission doubles loss of remission risk.

The TARGET-IBD registry was used to analyze predictors of LOR among CD patients in steroid-free endoscopic remission, with histologic inflammation and ileal disease identified as independent predictors using logistic regression, funded by Bristol Myers Squibb.

First major conference presentation of the CD histologic LOR findings establishes the evidence foundation for histologic remission as a treat-to-target endpoint in CD, supporting prescriber adoption of deeper remission goals and informing BMS's regulatory and commercial strategy for CD therapies.

First dissemination of histologic inflammation as CD LOR predictor for deep remission endpoint advocacy, Real-world CD histologic remission evidence supporting treat-to-target guideline development, Evidence base for histologic healing as an additional CD treatment target for next-generation IBD therapies